ORIC Pharmaceuticals, Inc. (ORIC)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
11.31 USD
-0.50
(-4.234%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 11.31 |
Hot Take ↕ | Oct. 10, 2026, 7:37 a.m. EDT
The investment case here is fractured by a stark disconnect between analyst optimism and market reality. While Wall Street rates this as a 'strong buy' based on potential royalty economics and Phase 3 progress, the stock has been decimated over the last five years, dropping nearly half its value. The recent news cycle highlights safety concerns at higher doses for their prostate cancer candidate, which likely explains why the stock is trading so far below the $21 analyst target. Fundamentally, the company is burning cash with negative free cash flow and negative returns on equity, relying entirely on capital markets to survive. The options market confirms this skepticism, with traders buying protection against a drop rather than betting on a rally. Until the clinical data resolves these safety concerns and revenue streams materialize, this remains a speculative hold with significant downside risk. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.199395 |
| AutoARIMA | 0.208809 |
| AutoTheta | 0.211434 |
| AutoETS | 0.214805 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.522 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.573 |
| Market Cap | 1,172,311,552 |
| Forward P/E | -6.76 |
| Beta | 0.98 |
| Website | https://www.oricpharma.com |
As of Oct. 10, 2026, 7:37 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes below the current price ($10 and $12), while call interest remains thin and concentrated at out-of-the-money strikes ($14-$15). This imbalance suggests a fear of further downside rather than a bullish bet on a breakout, despite the company's 'strong buy' analyst consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.10258359 |
| Address1 | 240 E. Grand Ave |
| Address2 | 2nd Floor |
| All Time High | 40.81 |
| All Time Low | 2.36 |
| Ask | 14.52 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,487,980 |
| Average Daily Volume3 Month | 1,478,293 |
| Average Volume | 1,478,293 |
| Average Volume10Days | 1,487,980 |
| Beta | 0.98 |
| Bid | 8.36 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 3.679 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.31 |
| Current Ratio | 13.186 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 11.915 |
| Day Low | 11.29 |
| Debt To Equity | 1.573 |
| Display Name | ORIC Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -154,995,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.894 |
| Enterprise Value | 913,548,544 |
| Eps Current Year | -1.49083 |
| Eps Forward | -1.67333 |
| Eps Trailing Twelve Months | -1.32 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.0075 |
| Fifty Day Average Change | -1.6974993 |
| Fifty Day Average Change Percent | -0.13050158 |
| Fifty Two Week Change Percent | -10.258359 |
| Fifty Two Week High | 14.68 |
| Fifty Two Week High Change | -3.37 |
| Fifty Two Week High Change Percent | -0.22956403 |
| Fifty Two Week Low | 7.23 |
| Fifty Two Week Low Change | 4.0800004 |
| Fifty Two Week Low Change Percent | 0.5643154 |
| Fifty Two Week Range | 7.23 - 14.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,587,735,000,000 |
| Float Shares | 88,688,322 |
| Forward Eps | -1.67333 |
| Forward P E | -6.758978 |
| Free Cashflow | -68,834,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 111 |
| Fullday Change | -0.5 |
| Fullday Change Percent | -4.2337003 |
| Fullday Price | 11.31 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01587 |
| Held Percent Institutions | 1.23138 |
| Implied Shares Outstanding | 103,652,656 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California. |
| Long Name | ORIC Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,172,311,552 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_303713108 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -140,351,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,379,616,851 |
| Number Of Analyst Opinions | 14 |
| Open | 11.68 |
| Operating Cashflow | -111,638,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Phone | 650 388 5600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 11.31 |
| Post Market Time | 1,791,921,671 |
| Previous Close | 11.81 |
| Price Eps Current Year | -7.5863786 |
| Price Hint | 2 |
| Price To Book | 3.0742052 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.756 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.5 |
| Regular Market Change Percent | -4.2337 |
| Regular Market Day High | 11.915 |
| Regular Market Day Low | 11.29 |
| Regular Market Day Range | 11.29 - 11.915 |
| Regular Market Open | 11.68 |
| Regular Market Previous Close | 11.81 |
| Regular Market Price | 11.31 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 1,158,226 |
| Return On Assets | -0.25969 |
| Return On Equity | -0.39801997 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,652,656 |
| Shares Percent Shares Out | 0.1574 |
| Shares Short | 16,315,970 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 17,266,340 |
| Short Name | Oric Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1591 |
| Short Ratio | 11.16 |
| Source Interval | 15 |
| State | CA |
| Symbol | ORIC |
| Target High Price | 27.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 21.42857 |
| Target Median Price | 22.5 |
| Total Cash | 264,760,992 |
| Total Cash Per Share | 2.554 |
| Total Debt | 5,998,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.948725 |
| Two Hundred Day Average Change | 0.36127567 |
| Two Hundred Day Average Change Percent | 0.032997057 |
| Type Disp | Equity |
| Volume | 1,158,226 |
| Website | https://www.oricpharma.com |
| Zip | 94,080 |